One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
Home ➤ Life Science ➤ Diagnostics ➤ Alzheimer’s Disease Therapeutics Market
Alzheimer’s Disease Therapeutics Market
Alzheimer’s Disease Therapeutics Market
Published date: Jan 2024 • Formats:
Request Sample Schedule a Call
  • Home ➤ Life Science ➤ Diagnostics ➤ Alzheimer’s Disease Therapeutics Market

Global Alzheimer’s Disease Therapeutics Market By Drug Class (Cholinesterase inhibitors, NMDA Receptor Antagonist Combination Drug, and Pipeline Drugs), By Disease Stage (Preclinical Alzheimer's Disease, Mild Cognitive Impairment (MCI), Mild Dementia Due to AD, Moderate Dementia Due to AD, and Severe Dementia Due to AD), By Route of Administration, By Distribution Channel, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

  • Published date: Jan 2024
  • Report ID: 105553
  • Number of Pages: 275
  • Format:
  • Overview
  • Table of Contents
  • Major Market Players
  • Request a Free Sample
  • Quick Navigation

    • Report Overview
    • Key Takeaways
    • Driving Factors
    • Restraining Factors
    • Drug Class Analysis
    • Disease Stage Analysis
    • Route of Administration Analysis
    • Distribution Channel Analysis
    • Key Market Segments
    • Growth Opportunity
    • Latest Trends
    • Regional Analysis
    • Key Players Analysis
    • Recent Developments
    • Report Scope

    Report Overview

    The Global Alzheimer’s Disease Therapeutics Market size is expected to be worth around USD 30.8 Billion by 2033 from USD 5.5 Billion in 2023, growing at a CAGR of 18.8% during the forecast period from 2024 to 2033.

    Alzheimer’s is described as a chronic brain condition that often leads to dementia in old individuals. This disease impairs an individual’s memory, and cognitive function, and disturbs the daily routine. Old age significantly raises the possibility of developing this condition. Certain genes have been linked to the disease. The APOE-e4 allele is the most well-known risk gene. Other risk factors include cardiovascular disease, high blood pressure, diabetes, stroke, and other conditions associated with vascular health. There is no single test for Alzheimer’s disease.

    Generally, healthcare professionals diagnose it by reviewing health records, conducting thorough health checkups, and sometimes using brain scans. A conclusive identification often comes after one has passed away, through brain analysis. There is no permanent cure for Alzheimer’s disease.

    However, the symptoms can be managed by several drugs. The rise in the prevalence of Alzheimer’s Disease (AD) as well as the approval of disease-modifying therapies is anticipated to surge the market growth. Furthermore, Alzheimer’s disease is becoming the most common cause of death in neurodegenerative diseases and also a common cause of physical disability which requires instant treatment.

    • In 2021, the National Center for Biotechnology Information reported that approximately 6.2 million individuals aged 65 and over in the U.S. had Alzheimer’s disease. This number is projected to rise to nearly 13.8 million by 2060.

    Alzheimer’s Disease Therapeutics Market Size

    Key Takeaways

    • In 2023, the Alzheimer’s disease therapeutics market was worth USD 5.5 billion.
    • By 2033, the market is expected to grow around USD 30.8 billion.
    • This Market’s growth is at a CAGR of 18.8% per year from 2024 to 2033.
    • North America dominates the global Alzheimer’s disease therapeutics market, with a 42.5% revenue share in 2023.
    • The rise in Alzheimer’s cases and the approval of new therapies are driving market growth.
    • In 2021, over 6.2 million people aged 65 and over had Alzheimer’s in the U.S., projected to reach nearly 13.8 million by 2060.
    • The aging population is a significant factor contributing to market growth.
    • Advances in diagnostic tools have led to earlier and more accurate Alzheimer’s diagnoses.
    • The disease is complex, with multiple potential causes and mechanisms, making drug development challenging.
    • Many Alzheimer’s drug candidates fail in clinical trials, leading to financial losses and reduced research investments.
    • Cholinesterase inhibitors are the dominant drug class for Alzheimer’s treatment, making up 53.2% of the market in 2023.
    • Mild cognitive impairment (MCI) is the most common disease stage in 2023. Accounted 33.7% market share.
    • Oral administration is the primary route for Alzheimer’s drugs, making up the majority of the market accounted 58.1% market share.
    • Hospital pharmacies are the largest distribution channel for Alzheimer’s drugs, with 56.4% of the market share in 2023.

    Driving Factors

    Rising geriatric population boosts the market growth

    The onset of Alzheimer’s disease is closely related to the increase in number of aged individuals. With the rise in life expectancy and an overall increase in the elderly population worldwide, particularly in developed nations, there is a consistent growth in the number of individuals that are vulnerable to Alzheimer’s disease.

    This demographic shift witnessed that healthcare systems will face mounting challenges related to age-related diseases, including Alzheimer’s disease. This will increase the need for effective treatments even more.

    Diagnostic Advances to surge to market growth

    The evolution of diagnostic tools, mainly in neuroimaging and molecular biomarkers, has led to the earlier and more accurate diagnosis of Alzheimer’s disease. Detecting the disease at an early stage allows for timely interventions. This can potentially slow down the disease progression. An earlier diagnosis would lead to the expansion of patient pool who can benefit from these treatments.

    Restraining Factors

    Complex disease pathology to restrict the expansion of the Alzheimer’s disease therapeutics market

    Alzheimer’s is one of the most complex diseases. It has multiple potential causes and mechanisms. This multifactorial nature means that targeting just one aspect of the disease might not yield effective or comprehensive treatments. This makes drug development more challenging.

    High clinical trial failure rates to hamper the market growth

    The drug development process for Alzheimer’s has been perforated with hindrances. The majority of potential treatments that appeared to be promising in early-stage research or even in preliminary clinical trials ended up failing in the subsequent phases.

    These frequent failures might be due to lack of efficacy or unexpected side effects. This leads to financial losses and is likely expected to limit future investments in research and development within this field.

    Drug Class Analysis

    Cholinesterase inhibitors accounted as the dominant segment in the global Alzheimer’s Disease Therapeutics market

    Based on drug class, the market for Alzheimer’s disease therapeutics is segmented into cholinesterase inhibitors, NMDA receptor antagonists, combination drugs, and pipeline drugs. Among these drugs, the cholinesterase inhibitors segment held the largest revenue share of 53.2% in 2023 as it is considered as the standard treatment for AD. These drugs work by inhibiting the breakdown of acetylcholine, which is a neurotransmitter.

    Neurotransmitter plays a crucial role in memory and cognitive function, which in turn increases its levels in the brain and improve the symptoms of the disease. Moreover, the segment growth is driven by increasing prevalence of AD. On the other hand, the pipeline drugs segment is projected to witness the fastest growth during the forecast period. This growth can be highly attributed to the impending launch of multiple disease-modifying therapies.

    Disease Stage Analysis

    Mild cognitive impairment (MCI) accounted as the dominant segment in 2023

    Based on disease stage, the market is divided into preclinical Alzheimer’s disease, mild cognitive impairment (MCI), mild dementia due to AD, moderate dementia due to AD, and severe dementia due to AD. Among these stages, mild cognitive impairment (MCI) accounted for a 33.7% market share as it is quite common, especially among aged individuals.

    • According to the American Academy of Neurology, it is estimated that mild cognitive impairment (MCI) is present in approximately 8 % of people aged 65 to 69, 15% of people aged 75 to 79, 25% of people aged 80 to 84, 37% of people 85 or older.

    However, not all cases of MCI progress to Alzheimer’s disease.

    Route of Administration Analysis

    The oral segment held the largest revenue share in 2023

    By route of administration, the market is divided into oral and injectable. Among these routes, the oral segment accounted for 58.1% of revenue share in 2023. Cholinesterase inhibitors such as donepezil, rivastigmine, galantamine, and memantine are the primary medications approved for the treatment of AD.

    These drugs are generally taken orally. The segment growth can be attributed to the ease of administration and painless drug delivery. Moreover, patients can self-administer the drug at home, workplace, and in travel.

    Distribution Channel Analysis

    Based on the distribution channel, the global Alzheimer’s disease market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. Among these segments, hospital pharmacies dominated the market with the largest share of 56.4%.

    The significant share is gained due to increasing hospitalization of patients with AD. Moreover, the segment growth is also enhanced by the rising geriatric population which leads to a higher number of AD cases. This leads to the increased sale of AD drugs from hospital pharmacies.

    • As per the 2022 report from the Alzheimer’s Association, geriatric Medicare beneficiaries with Alzheimer’s or other dementias experienced 518 hospitalizations per 1,000 individuals. In contrast, those without these conditions had a significantly lower rate, with only 234 hospitalizations per 1,000 beneficiaries.

    Alzheimer’s Disease Therapeutics Market Share

    Key Market Segments

    By Drug Class

    • Cholinesterase inhibitors
    • NMDA Receptor Antagonist
    • Combination Drug
    • Pipeline Drugs

    By Disease Stage

    • Preclinical Alzheimer’s disease
    • Mild cognitive impairment (MCI)
    • Mild dementia due to AD
    • Moderate dementia due to AD
    • Severe dementia due to AD

    By Route of Administration

    • Oral
    • Injectable

    By Distribution Channel

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Growth Opportunity

    Biomarker development to create numerous growth opportunities

    Biomarkers serve as the measurable indicators of disease states or conditions. Identifying specific indicators for Alzheimer’s disease can significantly enhance the way of diagnosing and measuring the disease’s stage, progression, and reaction to treatments.

    Increase in funding and studies in this field can help in initiating the treatments sooner and tailoring them more effectively. This in turn leads to improved results for patients.

    Latest Trends

    Advancements in immunotherapy & digital health solutions to boost the market growth

    Immunotherapy involves the use of body’s immune system to target and remove the harmful substances, such as beta-amyloid plaques in Alzheimer’s disease. Aducanumab, an example of an immunotherapy drug, gained attention for its potential to clear beta-amyloid plaques. Ongoing research aims to refine the dosing, delivery methods, and patient selection criteria for immunotherapies.

    Moreover, digital tools like cognitive assessment apps, wearable devices, and remote monitoring systems offer the ability to track cognitive decline and other symptoms remotely. These technologies provide real-time data that can be used to personalize treatment plans and monitor the effectiveness of interventions over time.

    Regional Analysis

    North America dominated the global Alzheimer’s disease therapeutics market with a revenue share of 42.5%

    Based on region, the global Alzheimer’s disease therapeutics market is divided into North America, Europe, Asia Pacific, Latin America, And Middle East & Africa. Among these regions, North America accounted for the dominant region with the highest revenue share of 42.5% in 2023.

    This significant share is gained due to the growing research for the treatment of Alzheimer’s disease in the region. In addition, the growth of this region is also influenced by the increasing government initiatives and funding.

    • In June 2021, the U.S. FDA granted the Breakthrough Therapy designation to lecanemab (BAN2401), an anti-amyloid beta protofibril antibody developed by Eisai Co., Ltd. and Biogen for Alzheimer’s disease treatment.

    The Asia-Pacific is projected to grow at the highest CAGR during the forecast period

    The market of Asia-Pacific is expected to be propelled by increasing research activities to develop novel drugs for treatment of Alzheimer’s disease. In addition, the increasing awareness regarding AD is likely expected to fuel the market growth of this region.

    Alzheimer’s Disease Therapeutics Market Region

    Key Regions

    • North America
      • The US
      • Canada
      • Mexico
    • Western Europe
      • Germany
      • France
      • The UK
      • Spain
      • Italy
      • Portugal
      • Ireland
      • Austria
      • Switzerland
      • Benelux
      • Nordic
      • Rest of Western Europe
    • Eastern Europe
      • Russia
      • Poland
      • The Czech Republic
      • Greece
      • Rest of Eastern Europe
    • APAC
      • China
      • Japan
      • South Korea
      • India
      • Australia & New Zealand
      • Indonesia
      • Malaysia
      • Philippines
      • Singapore
      • Thailand
      • Vietnam
      • Rest of APAC
    • Latin America
      • Brazil
      • Colombia
      • Chile
      • Argentina
      • Costa Rica
      • Rest of Latin America
    • Middle East & Africa
      • Algeria
      • Egypt
      • Israel
      • Kuwait
      • Nigeria
      • Saudi Arabia
      • South Africa
      • Turkey
      • United Arab Emirates
      • Rest of MEA

    Key Players Analysis

    Emerging key players in the market are highly investing in R&D for introduction of novel drugs and therapies for the treatment of alzheimer’s disease. In addition, they are focused on implementing the strategic growth policies to increase their market presence.

    Moreover, they are involved in partnerships, collaborations, and mergers & acquisitions. Successful launch of drugs, which reduce amyloid-β plaques and moderately slows mild cognitive decline in patients with early Alzheimer’s disease is expected to fuel the market growth during the forecast period.

    Market Key Players

    • Eisai Co., Ltd.
    • Novartis AG
    • AbbVie Inc. (Allergan Plc.)
    • Adamas Pharmaceuticals, Inc.
    • Lundbeck A/S
    • Biogen
    • AC Immune
    • Hoffmann La Roche Ltd.
    • Daiichi Sankyo Company, Limited
    • Johnson & Johnson Services, Inc.
    • TauRx Pharmaceuticals Ltd.
    • Other Key Players

    Recent Developments

    • In January 2023, the U.S. Food and Drug Administration (FDA) granted approval for Leqembi (lecanemab-irmb), a drug developed by Eisai Co., Ltd., for the treatment of Alzheimer’s disease.
    • In March 2022, the U.S. Food and Drug Administration (FDA) granted approval to Adlarity (donepezil hydrochloride), a cholinesterase inhibitor formulated by Corium Inc., for the treatment of individuals with severe Alzheimer’s disease-related dementia.

    Report Scope

    Report Features Description
    Market Value (2023) USD 5.5 Billion
    Forecast Revenue (2033) USD 30.8 Billion
    CAGR (2024-2033) 18.8%
    Base Year for Estimation 2023
    Historic Period 2018-2022
    Forecast Period 2024-2033
    Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments
    Segments Covered By Drug Class (Cholinesterase inhibitors, NMDA Receptor Antagonist, Combination Drug, Pipeline Drugs); By Disease Stage (Preclinical Alzheimer’s disease, Mild cognitive impairment (MCI), Mild dementia due to AD, Moderate dementia due to AD, Severe dementia due to AD); By Route of Administration (Oral, Injectable); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA
    Competitive Landscape Eisai Co., Ltd., Novartis AG, AbbVie Inc. (Allergan Plc.), Adamas Pharmaceuticals, Inc., H. Lundbeck A/S, Biogen, AC Immune, F. Hoffmann La Roche Ltd., Daiichi Sankyo Company, Limited, Johnson & Johnson Services, Inc., TauRx Pharmaceuticals Ltd. Other Key Players
    Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
    Purchase Options We have three license to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)

    Frequently Asked Questions (FAQ)

    What is the Alzheimer’s Disease Therapeutics Market?

    The Alzheimer's Disease Therapeutics Market refers to the industry focused on developing and providing treatments for Alzheimer's disease, a neurodegenerative condition affecting memory and cognitive function.

    How big is the Alzheimer’s Disease Therapeutics Market?

    The global Alzheimer’s Disease Therapeutics Market size was estimated at USD 5.5 Billion in 2023 and is expected to reach USD 30.8 Billion in 2033.

    What is the Alzheimer’s Disease Therapeutics Market growth?

    The global Alzheimer’s Disease Therapeutics Market is expected to grow at a compound annual growth rate of 18.8%. From 2024 To 2033

    Who are the key companies/players in the Alzheimer’s Disease Therapeutics Market?

    Some of the key players in the Alzheimer’s Disease Therapeutics Markets are Eisai Co., Ltd., Novartis AG, AbbVie Inc. (Allergan Plc.), Adamas Pharmaceuticals, Inc., H. Lundbeck A/S, Biogen, AC Immune, F. Hoffmann La Roche Ltd., Daiichi Sankyo Company, Limited, Johnson & Johnson Services, Inc., TauRx Pharmaceuticals Ltd. Other Key Players.

    What types of therapeutics are commonly used for Alzheimer’s disease?

    Common therapeutics for Alzheimer's disease include cholinesterase inhibitors and NMDA receptor antagonists, aimed at managing symptoms and slowing disease progression.

    Are there any promising advancements in Alzheimer’s therapeutics?

    Emerging therapies, including monoclonal antibodies and disease-modifying drugs, show promise in addressing the underlying causes of Alzheimer's disease, offering hope for more effective treatments.

    What role does research and development play in this market?

    Research and development efforts are critical in advancing Alzheimer's therapeutics, as they lead to the discovery of new drugs and treatment approaches, driving market growth.

    Alzheimer’s Disease Therapeutics Market
    Alzheimer’s Disease Therapeutics Market
    Published date: Jan 2024
    add_shopping_cartBuy Now get_appDownload Sample
    keyboard_arrow_up
    • Eisai Co., Ltd.
    • Novartis AG Company Profile
    • AbbVie Inc. (Allergan Plc.)
    • Adamas Pharmaceuticals, Inc.
    • Lundbeck A/S
    • Biogen
    • AC Immune
    • Hoffmann La Roche Ltd.
    • Daiichi Sankyo Company, Limited
    • Johnson & Johnson Services, Inc.
    • TauRx Pharmaceuticals Ltd.
    • Other Key Players
  • settingsSettings

Related Reports

  • Acute Ischemic Stroke Therapeutics Market
  • Peptide Therapeutics Market
  • Leukemia Therapeutics Market
  • Gout Therapeutics Market
  • Cystic-Fibrosis Therapeutics Market
  • Sinus Therapeutic Drug Market
  • Aquaculture Therapeutics Market

Our Clients

  • Our Clients
Inquiry Before Buying

Alzheimer’s Disease Therapeutics Market
  • 105553
  • Jan 2024
    • ★★★★★
      ★★★★★
    • (63)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • All Reports
  • All Sectors
  • Infographics
  • Statistics and Facts
  • Companies
Secured Payment Options
Secured Payment Options

© 2025 Market.Us. All Rights Reserved.